Pharmacolog signs a collaboration agreement with researchers at Uppsala University regarding antibiotic treatment
Pharmacolog AB has entered a research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood during treatment of patients with severe infections.
Antibiotic treatment with the right dose is crucial for patients to survive severe infections. Today, technology is lacking to quickly determine blood concentrations of antibiotics in patients treated for serious infections. The collaboration between Pharmacolog AB and Professor Miklos Lipcsey at the Department of Surgical Sciences and Professor Anders Larsson at the Department of Medical Sciences, both at Uppsala University, is a result of preparatory tests of the ability to measure the antibiotic concentration in blood with Pharmacolog’s current technology. The collaboration will continue until December 2017 with the aim of developing a method for rapidly and patiently determining blood levels of antibiotics in patients treated for severe infections.
Hans Dahlin, Founder and Research Director at Pharmacolog: “I am extremely pleased that after a time of preliminary tests we can start this important research project with two outstanding experts on antibiotic treatment of severe infections. The project is well within our vision of participating in research projects that can lead to the development of new products for patient-controlled controls of intravenous drug treatments of severe diseases such as sepsis and cancer.”
Dr. Miklos Lipcsey, anesthetist and researcher Academic Hospital: “Healthcare is facing major challenges regarding the use of antibiotics. The correct dose is necessary to cure difficult infections but also a prerequisite for preventing resistance development. The research collaboration with Pharmacolog is very interesting given the great need for rapid analysis and measures in the treatment of antibiotics in severe infections. Several studies have shown that delayed or insufficient initial antibiotic treatment leads to significantly increased mortality in sepsis. We have already received some interesting promising results that we now hope through this project will result in scientific work that can contribute to new products for safer and more patient-adapted antibiotic treatment.”
Successful collaboration with Swedish university hospital enters the next phase
Pharmacolog has, in collaboration with one of the leading university hospitals in Sweden, developed ARM (Advanced Reconstruction Module). The system will be tested in clinical environments for 6 months and comprises 2 DrugLog systems that will be rented during the project period.
Astrid Lindgren’s Children’s Hospital at Karolinska University Hospital will with funding from SLL Innovation to undertake a 6-month project to test the Advanced Reconstruction Module (ARM) with its associated DrugLog® in a clinical environment. The project runs throughout the year and includes the lease of two DrugLog systems.
The ARM, partly funded by Vinnova, was implemented during the second half o...
New company analysis of Pharmacolog AB performed by Jarl Securities. Read the complete analysis here (in Swedish only): https://www.aktiespararna.se/sites/default/files/pharmacolog_2017-06-13.pdf
First order from France
Pharmacolog’s distributor has ordered a first system to be placed at Hôspital du Confluent in Nantes. The system shall be used for the final control of chemotherapy drugs toxicity at the hospital pharmacy. Pharmed won the order in competition with other suppliers.
During 2016, Pharmed has deliberately processed the French market, focusing on hospital pharmacies that prepare for chemotherapy and has now placed the first order on a DrugLog system. The system will be placed at the Hôspital du Confluent in Nantes and will be used for the final control of chemotherapy drugs prepared made at the hospital pharmacy. The deal means that, according to agreement, Pharmed purchases a DrugLog® systems f...
Pharmacolog Appoints New Sales and Marketing Manager
Pharmacolog appoints Kent Öbrink as new Sales and Marketing Manager. Kent has more than 20 years of experience in qualified healthcare sales and a solid international experience. Kent will start on 1 of June and comes from C-Rad AB, where he held the role of Global Sales Manager.
As sales and marketing manager, Kent Öbrink will be responsible for the company’s commercial activities and for collecting important market intelligence before new development projects. Kent is a qualified microbiologist, but soon entered sales and marketing with a job as a Sales Representative at Kabi Pharmacia in 1991. After that, Kent held several qualified sales manager positions within the company until 1999, ...